RPCEC00000008CompletedPhase 2
Active specific immunotherapy with 1E10 anti-idiotype vaccine to treat patients with metastatic breast cancer, phase II.
Center of Molecular Immunology (CIM)0 sites80 target enrollmentStarted: December 27, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Treatment
Eligibility Criteria
- Ages
- 18 years to 80 years (—)
- Sex
- Female
Inclusion Criteria
- •1)Female patients with cyto- ’histological confirmed diagnostic of recurrent or Stage IV metastatic breast cancer 2)Patients that have received the oncospecific therapy according to the treatment guidelines established in the country and that have ended the different protocols in a time period of 4 weeks prior to entry in the trial. 3)Patient’s informed consent to participate in the investigation obtained. 4)Age = 18 years. 5)Patients with life expectancy = 6 months. 6)Performance Status according to WHO from 0 to 2. 7)Clinical laboratory parameters: a.-) Hematopoietic parameters: - Hb>100g/l, - Leucocytes>4 x 109cells/l - Granulocytes>2x109 cells/l, - Platelets> 100 x 109cells/ l. b.-) Liver (not exceeding the normal upper limit by three times), bilirubin: 17mol/l (LSN), ALAT: 40U/l (LSN), ASAT: 40U/l (LSN), alkaline phosphatase: 279U/l c.-) Kidney: serum creatinine: 132 mmol/l.
Exclusion Criteria
- •1.Patients with breast cancer in stage Iv or recurrent diseases that have received oncospecific therapy and have concluded the different protocols in a time period inferior to 4 weeks or greater than 4 weeks prior to entry in the trial. 2.Pregnant or breastfeeding patients. 3.Patients with prior history of demielinizing disease or inflammatory disease of the CNS or the peripheral nervous system. 4.Patients with previous malignancies except carcinoma in situ of cervix or skin cancer (not melanoma), treated properly. 5.Patients with acute or chronic infectious diseases. 6.Patients with acute allergic status or history of severe allergic reactions. 7.Patients with autoimmune diseases or chronic non-compensated diseases. 8.Patients who present the contralateral breast as the only site of metastatic disease.
Investigators
Similar Trials
Completed
Phase 2
1E10 anti-idiotype vaccine, metastatic colon, phase II.Colon adenocarcinoma phase IV or evolvable metastatic diseaseColonic NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesColorectal NeoplasmsRPCEC00000006Center of Molecular Immunology (CIM)40
Completed
Phase 2
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patientsAdvanced Lung Cancer Small Cell Lung CancerSmall Cell Lung CarcinomaCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000010Center of Molecular Immunology (CIM)88
Recruiting
Phase 1
GcGM3/VSSP in small cell lung cancerCarcinoma, BronchogenicRespiratory Tract NeoplasmsLung NeoplasmsSmall cell lung cancerBronchial NeoplasmsSmall Cell Lung CarcinomaThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000224Center of Molecular Immunology (CIM)40
Recruiting
Phase 2
GcGM3/VSSP in Metastatic melanomaMetastatic melanomaNevi and MelanomasNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueMelanomaRPCEC00000223Center of Molecular Immunology (CIM)160
Not yet recruiting
Phase 2
GcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancerMetastatic hormone-receptor positive and HER2 negative breast cancerBreast NeoplasmsBreast DiseasesRPCEC00000220Center of Molecular Immunology (CIM)286
